With expertise in biostatistics, multimodal data integration, and regulatory-compliant data analysis, Joel Baublits delivers precise, actionable insights for cardiovascular, respiratory, and toxicology studies.

Endpoint Preclinical is proud to welcome Joel Baublits, MS, to our Expert Network. As the co-founder of Cardiovascular Analytics (CVA), Joel specializes in biostatistics and multimodal data analysis for preclinical research, supporting safety pharmacology, toxicology evaluations, and regulatory submissions. His extensive experience in integrating complex datasets ensures statistically sound interpretations that inform critical research decisions and product development. View Joel’s Profile

Biostatistics and Multimodal Data Integration: Joel brings a wealth of experience in statistical methods and data integration, ensuring robust analysis of preclinical datasets. Key capabilities include:

• Advanced Statistical Analysis: Application of techniques using SAS, R, and Prism to generate comprehensive insights from cardiovascular, respiratory, and toxicology datasets.
• Multimodal Data Integration: Merging data from physiological monitoring systems to deliver cohesive and precise analyses of study endpoints.
• Regulatory-Compliant Analytics: Providing GLP-compliant analysis that aligns with FDA standards for safety pharmacology and toxicology studies.

Cardiovascular, Respiratory, and Toxicology Data Analysis: Joel excels in interpreting critical physiological data to support safety and efficacy evaluations. His expertise includes:

• ECG Analysis: Assessing parameters such as QT intervals, PR segments, and arrhythmias to ensure regulatory readiness.
• Respiratory Function Analysis: Evaluating endpoints like tidal volume, minute ventilation, and respiratory rates, integrated seamlessly with cardiovascular data.
• Toxicological Outcomes: Delivering detailed analyses of acute and chronic toxicity endpoints to support GLP studies.

Study Design and Reporting: With experience as a Study Director and Principal Investigator, Joel supports clients in developing preclinical protocols and generating high-quality reports tailored to study objectives.

Joel emphasizes precision and clarity in data reporting, ensuring clients receive:

• Actionable Insights: Robust, reliable data interpretations for regulatory submissions and product development.
• Tailored Reports: Customized outputs aligned with S7B/E14 guidance and specific client needs, balancing thoroughness with rapid turnaround times.

Joel’s expertise supports a broad range of preclinical research applications, including:

• Safety Pharmacology: Evaluating the cardiac and respiratory safety of new therapeutics.
• Toxicology Studies: Providing robust data analysis for acute and chronic toxicity evaluations.
• Efficacy Research: Supporting pharmacologic interventions with detailed data insights.

Join us in welcoming Joel Baublits to Endpoint Preclinical. His expertise in biostatistics and multimodal data integration strengthens our ability to deliver high-quality, regulatory-compliant solutions for cardiovascular, respiratory, and toxicology studies. Contact us to learn how Joel can support your preclinical research needs.